ArticleF&S reports2025
Extending letrozole dosing in patients with polycystic ovary syndrome undergoing ovulation induction with intrauterine insemination.
Article in F&S reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the effect of prescribing a second course of letrozole within a single ovulation induction/intrauterine insemination (OI/IUI) cycle on pregnancy outcomes in patients with polycystic ovary syndrome (PCOS). Design: Retrospective cohort study. Subjects: Cases designated as OI/IUI in PCOS patients using letrozole alone for OI were identified. Patient (n = 183) and cycle (n = 405) demographics and outcomes were collected. Cycles in which an adequate response was achieved with a single course of letrozole (n = 333) were compared with cycles in which a second course was needed to achieve adequate follicular growth (n = 72). A second course was indicated in cases of suboptimal follicular growth after the initial course of letrozole. The relationships between single vs. a second course and pregnancy-related outcomes were examined adjusting for age and body mass index in logistic regressions. Exposure: Extended dosing with a second course of letrozole within an OI/IUI cycle in PCOS patients. Main Outcome Measures: Clinical pregnancy. Results: The clinical pregnancy rate was not significantly different for the extended-dose cycles (15.3%,11/72) compared with single-dose cycles (13.5%, 45/333) (odds ratio [95% confidence limit] = 1.15 [0.56-2.36]). After adjusting for age and body mass index, there remained no significant difference between groups. Conclusion: Extended dosing with a second course of letrozole in an OI/IUI cycle is associated with no significant difference in pregnancy and live birth outcomes. Thus, it is reasonable to give a second course of letrozole in a patient with PCOS, if indicated, which helps optimize the number of cycles needed to achieve pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.